4.5 Article

ASK1 suppresses NK cell-mediated intravascular tumor cell clearance in lung metastasis

Journal

CANCER SCIENCE
Volume 112, Issue 4, Pages 1633-1643

Publisher

WILEY
DOI: 10.1111/cas.14842

Keywords

ASK1; intravascular tumor cell clearance; lung metastasis; NK cell; NKG2D

Categories

Funding

  1. Japan Society for the Promotion of Science [18K19469, JP15K14445, JP17H06419, JP18H02569, JP18H03995, JP18K19469, JP26114009]
  2. Yasuda Memorial Medical Foundation [2017Y-1]
  3. Japan Agency for Medical Research and Development [JP20gm5010001]
  4. Japan Science and Technology Agency [JPMJMS2022-18]
  5. Grants-in-Aid for Scientific Research [18K19469] Funding Source: KAKEN

Ask authors/readers for more resources

The study demonstrates that ASK1 deficiency promotes NK cell-mediated intravascular tumor cell clearance and upregulates immune response-related genes, including IFN gamma, to enhance the anti-metastatic phenotypes. NK cells are required for these anti-metastatic phenotypes.
Tumor metastasis is the leading cause of death worldwide and involves an extremely complex process composed of multiple steps. Our previous study demonstrated that apoptosis signal-regulating kinase 1 (ASK1) deficiency in mice attenuates tumor metastasis in an experimental lung metastasis model. However, the steps of tumor metastasis regulated by ASK1 remain unclear. Here, we showed that ASK1 deficiency in mice promotes natural killer (NK) cell-mediated intravascular tumor cell clearance in the initial hours of metastasis. In response to tumor inoculation, ASK1 deficiency upregulated immune response-related genes, including interferon-gamma (IFN gamma). We also revealed that NK cells are required for these anti-metastatic phenotypes. ASK1 deficiency augmented cytokine production chemoattractive to NK cells possibly through induction of the ligand for NKG2D, a key activating receptor of NK cells, leading to further recruitment of NK cells into the lung. These results indicate that ASK1 negatively regulates NK cell-dependent anti-tumor immunity and that ASK1-targeted therapy can provide a new tool for cancer immunotherapy to overcome tumor metastasis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available